Acadia's remlifanserin narrowly misses primary endpoint in Phase 2 Alzheimer's psychosis study
The company will proceed to Phase 3 with the 60 mg dose and drop the 30 mg arm after mixed Phase 2 RADIANT results.
SEC filing
Latest
4 stories
Tuesday, September 29
Thursday, September 24
Tuesday, August 11
Immunic adds Elena Ridloff to board ahead of Phase 3 MS readout
The company also detailed the separation terms for former CEO Daniel Vitt as he transitions to a consulting and advisory role.
SEC filing
Tuesday, August 4
Acadia raises 2026 revenue guidance on DAYBUE and NUPLAZID growth
The company also completed Phase 2 enrollment in its remlifanserin Alzheimer's psychosis program and won FDA Fast Track designation, with topline data expected in September to October 2026.
SEC filing